Blackrock SEC Filings

Rubrik, Inc. (RBRK) Form 4 filing dated 07/02/2025 discloses a single insider sale. Lightspeed Management Company, L.L.C. ("LMC") – a reporting person classified as a 10% owner and represented by managing members Barry Eggers, Ravi Mhatre and Peter Nieh – sold 16,984 Class A common shares on 06/30/2025 at a weighted-average price of $89.47. Following the transaction, LMC reports holding 0 shares directly.

The filing also lists the insiders’ residual indirect and direct positions that were not involved in the sale, including 59,182 shares held individually by Eggers, 59,182 shares held individually by Nieh, and several limited-partnership stakes totaling more than 800,000 shares across Eggers Investments LP-Fund 2 and four Nieh Family Investments LP funds.

No derivative security activity, 10b5-1 plan indication, or additional transactions were reported. The disposition represents a small fraction of the group’s overall Rubrik exposure and does not materially change their aggregate ownership status.

BlackRock, Inc. (BLK) Form 4 filing – 30 June 2025

Board member Hans E. Vestberg reported the award of 33 common shares on 30-Jun-2025 under the company’s 1999 Stock Award & Incentive Plan. The grant was valued at the day’s closing price of $1,049.25 per share but carried a cost basis of $0 to the director because it was an equity compensation award. Following the transaction, Vestberg’s direct beneficial ownership rises to 1,799 shares. No derivative securities were involved, and the filing does not reference any Rule 10b5-1 trading plan. The disclosure is routine and does not signal any change in corporate strategy or fundamentals.

BlackRock, Inc. (BLK) Form 4 filing dated 07/02/2025 reports that Board Director Charles H. Robbins received a routine equity award.

• Transaction date: 06/30/2025
• Security: BlackRock common stock (par value $0.01)
• Transaction code: A (grant under company equity plan)
• Number of shares granted: 28
• Reference price: $1,049.25 per share (closing price on grant date)
• Approximate award value: $29,379 (28 shares × $1,049.25)
• Post-transaction direct holdings: 2,796 shares
• Ownership type: Direct (D)
• Plan: Third Amended and Restated BlackRock, Inc. 1999 Stock Award and Incentive Plan (non-employee director compensation)

The filing shows no dispositions, derivative transactions, or 10b5-1 plan usage. The grant modestly increases Robbins’ stake but represents a standard annual director award rather than an open-market purchase, carrying limited signaling value for investors.

Modular Medical, Inc. (MODD) – Form 4 filed 07/02/2025

Director and 10% owner Morgan C. Frank disclosed the award of stock options granted on 06/30/2025 under the company’s Outside Director Compensation Plan:

• 1,875 options to buy common stock at an exercise price of $0.68, fully vested on the grant date, expiring 06/30/2035.
• 7,500 additional options on identical terms.

After these grants, Mr. Frank beneficially owns 9,375 derivative securities (stock options) directly. No changes in non-derivative (actual share) ownership were reported.

The filing records routine director compensation aligned with the company’s plan; it neither involves open-market purchases nor sales and therefore provides limited insight into near-term insider sentiment. The document does not disclose Modular Medical’s total shares outstanding, so the potential dilution impact of 9,375 options cannot be quantified from this filing alone.

Form 4 filing for The Walt Disney Company (DIS) reports that director Maria Elena Lagomasino acquired an aggregate 784.9 Disney common shares on 06/30/2025 at a reference price of $119.43 per share. The shares consist of:

• 282.5 stock units received in lieu of quarterly cash board-retainer fees
• 502.4 deferred stock units issued as the regular quarterly grant under Disney’s Amended & Restated 2011 Stock Incentive Plan

BlackRock, Inc. (BLK) filed a Form 4 reporting a director-level stock grant. On 30 June 2025, director Amin H. Nasser received 28 shares of BLK common stock under the company’s Third Amended & Restated 1999 Stock Award and Incentive Plan. The grant was priced for accounting purposes at $1,049.25 per share, the closing price on the grant date, implying an aggregate market value of roughly $29,400. Because the shares were awarded as director compensation, the transaction is coded “A” (acquisition) and shows a cash price of $0.

After the grant, Nasser’s beneficial ownership stands at 793 shares held directly and 142 shares held indirectly through a family trust. No derivative securities were reported, and no dispositions occurred.

The filing represents routine board compensation with immaterial dilution to existing shareholders. Nevertheless, it signals continued alignment between the director and shareholder interests through additional equity ownership.

Ligand Pharmaceuticals (LGND) – Form 4 insider activity

Chief Legal Officer & Secretary Andrew Reardon disclosed the purchase of 233 common shares on 30 Jun 2025 under the company’s Employee Stock Purchase Plan (Transaction Code J). The shares were acquired at an average price of $91.0775, an outlay of roughly $21,000. Following the transaction, Reardon’s direct beneficial ownership rose to 32,136 shares. The Form 4 was filed on 2 Jul 2025.

The transaction is routine ESPP participation rather than an open-market buy, so the immediate market impact is limited. Nevertheless, the filing shows continued executive equity accumulation, modestly reinforcing management–shareholder alignment.

On 30 June 2025, SANUWAVE Health, Inc. (ticker: SNWV) granted Director Jeffrey Blizard a fully-vested stock option covering 1,574 shares of common stock, as disclosed in a Form 4 filed on 2 July 2025. The option carries an exercise price of $32.86 and an expiration date of 30 June 2030. The transaction was coded “A,” indicating an issuer-awarded grant rather than an open-market purchase. No non-derivative transactions or additional derivative movements were reported.

Following this grant, Mr. Blizard directly owns 1,574 derivative securities and reported no other holdings in SNWV common stock. Because the options were already fully vested at issuance, they are immediately exercisable, potentially aligning the director’s incentives with shareholder value creation. However, the filing does not specify any accompanying cash outlay or further equity activity.

On July 1, 2025, Brink's Company (BCO) director Paul G. Boynton acquired 196 deferred stock units through the company's Director Fee Deferral Plan. Each unit is economically equivalent to one common share and was credited at $89.29, the closing price on the final trading day of the quarter. The units will convert to common stock on a one-for-one basis at a future date chosen by the director or upon termination of board service. Following the credit, Boynton now beneficially owns 10,099.95 deferred units. No shares were sold, and the filing reflects routine quarterly compensation rather than a discretionary market transaction; therefore, the impact on Brink's capital structure and public float is immaterial.